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Polycystic kidney disease (PKD) is associated with mutations
in PKD1 and PKD2 and vascular abnormalities. The links
between the epithelial and vascular defects, however, are
poorly understood. Vascular endothelial growth factor (VEGF)
has been shown to be critical for normal kidney
development. In animal models, blockade of VEGF in the
perinatal period can lead to abnormal glomerular
development, impaired nephrogenesis, proteinuria, and renal
failure. We hypothesized that brief blockade of VEGF
signaling during early postnatal kidney development can
lead to renal cyst development. On days 2 and 4 of life, CD-1
mice were treated with antibodies generated against the
extracellular portion of the VEGF receptor 2 (DC101), the area
of the receptor where VEGF binding occurs. Mice developed
renal cysts between 2 and 3 weeks. The DC101-treated mice
also had increased cell proliferation in the renal tubule
epithelium. In addition, mice receiving DC101 developed
abnormal glomeruli, proteinuria, and patchy cellular
infiltrates. Early disruption of VEGFR-2 signaling during the
perinatal period results in renal cyst formation, impaired
glomerulogenesis, and inflammation. VEGF could be a key
link between vascular and cystic changes in kidney cyst
formation.
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Vascular endothelial growth factor (VEGF) is critical for
normal glomerular development and nephrogenesis. Pre-
vious studies in perinatal mice have found that decreased
levels of VEGF, using VEGF-neutralizing antibodies or
transgenic mice, resulted in impaired glomerular growth
and subsequent renal failure.1,2 This dependence on VEGF
for normal kidney growth and survival, however, is age
dependent. Gerber et al.,3 found that mice given antibodies
during the first week of life manifested impaired glomer-
ulogenesis and subsequently died of renal failure at 1 week
of age. In contrast, when VEGF antibodies were given to
2-week-old mice, no adverse effects were noted in kidney
development. Others have demonstrated that VEGF has a
role as a maintenance factor in the adult kidney. It has been
proposed that VEGF regulates permeability in the glomeruli,
supported by its expression in glomerular podocytes.4
Furthermore, dysregulation of VEGF has been implicated
in different kidney diseases. Recently, it was shown that adult
mice given soluble VEGF receptor 1 (VEGFR-1), a negative
regulator of VEGF, developed proteinuria.5 Furthermore,
elevated levels of soluble VEGFR-1 were found in the serum
of women who developed pre-eclampsia, a disease in
pregnant women associated with proteinuria and renal
lesions.6
The majority of studies have focused on the effect of
VEGF dysregulation on the glomeruli. VEGF/VEGFR signal-
ing, however, may also be important for normal tubule
development and during injury repair. NRK52-E cells, a rat
tubule epithelial cell line, express both VEGFR-1 and VEGFR-
2. VEGF induces cell proliferation in these cells and decreases
apoptosis in cells exposed to hydrogen peroxide.7 VEGFR-2 is
also expressed in murine convoluted tubular cells, a
transformed murine proximal tubule epithelial cell line. In
these cells, VEGF through VEGFR-2 phosphorylation in-
creases protein synthesis through phosphatidylinositol
3-kinase activation.8 VEGF has been shown to induce tubule
epithelium cell growth and capillary formation in meta-
nephric organ culture.9 These studies suggest that in the
kidney VEGF/VEGFR-2 signaling may induce epithelial cell
proliferation through increased capillary development or
through a direct autocrine effect on the epithelial cell.
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Given the above data and in view of the unexplained
observation of vascular lesions in patients with polycystic
kidney disease (PKD), we hypothesized that VEGF would
mediate postnatal kidney cyst formation. We tested this
hypothesis by examining the effects of VEGF receptor
blockade in perinatal mice. We predicted that mice treated
in the perinatal period with the anti-VEGFR-2 antibody
DC101 would develop transient blockade of VEGF/VEGFR-2
signaling and that this would result in abnormal tubule
formation. We also expected that mice treated with DC101
would develop abnormal glomeruli as previously found in
other models.1–3 Furthermore, since MF1 antibodies block
both the soluble and membrane form of VEGFR-1, we
hypothesized that MF1 would also have a detrimental effect
on postnatal kidney development.
Because the half-life of DC101 and MF1 antibodies is
between 3 and 4 days, mice were only given antibodies on
days 2 and 4 of life. This was done in order to limit
glomerular injury and increase survival, so that mice could be
followed longitudinally with time. We found that by 2 and 3
weeks of age, mice treated with DC101 in the perinatal period
developed large renal cysts. DC101-treated mice also devel-
oped abnormal glomeruli. If mice, however, were given
DC101 after 2 weeks of age, they did not develop renal cysts.
In contrast, mice treated with MF1 alone had no early or late
histological changes in the kidney. These results indicate that
early VEGFR-2 blockade in the perinatal period alters both
tubule and glomerular development. Furthermore, develop-
ment of cyst formation secondary to VEGFR-2 blockade is
critically dependent on the time period in which VEGFR-2
signaling is impaired.
RESULTS
Development of renal cysts in mice treated with DC101 in the
perinatal period
At 2 weeks of age, mice treated with DC101 in the perinatal
period developed renal cysts. These cysts were variable in size,
located throughout the cortex, and lined with cuboidal cells
(Figure 1). By 3 weeks of age, renal cysts were significantly
larger in size when compared to 2-week-old DC101-treated
kidney. Cellular infiltrates were also seen in the cortex of
3-week-old DC101-treated kidney (orange arrows). Control
mice injected with immunoglobulin G in the perinatal period
did not develop dilated renal cysts at either 2 or 3 weeks of age.
Antibody localization in the kidney
In order to determine if VEGFR antibodies acted directly on
the kidney, DC101 antibodies were injected into 5-day-old
mice. At 2 h post injection, kidneys were removed and
processed for antibody staining. DC101 antibody staining
(red) was found to co-localize predominately with the
podocyte marker, synaptopodin (green) (Figure 2). In adult
mice, MF1staining was localized predominately in the
glomeruli (data not shown).
In order to identify the type of tubules undergoing cystic
changes following VEGFR-2 blockade, we used periodic acid
Schiff (PAS) staining and antibodies to angiotensin-convert-
ing enzyme. Although PAS and ACE staining are not
exclusively specific to proximal tubules, these stains are
useful, along with histological features, in identifying
proximal tubules. Some of the cysts of DC101-treated
kidneys had positive staining for PAS (Figure 3a–d, black
arrow). Larger cysts, however, had little or no PAS staining,
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Figure 1 | Cyst development in 2- and 3-week-old kidney from mice treated with DC101 in the perinatal period. (a–f) Multiple cysts
(a, b) developed in 2-week-old DC101-treated kidney. In 3-week-old DC101-treated kidney (d, e), cysts were significantly larger, black arrow
points to abnormal glomerulus and orange arrow points to cellular infiltrates. (g) Two- and 3-week-old DC101-treated kidney had significantly
larger cysts then 2- and 3-week-old control mice (*,**Po0.0001). Three-week-old DC101-treated kidney had significantly larger cysts then
2-week-old DC101-treated kidney (zPo0.001). (h) Renal cysts number was significantly larger in 2- and 3-week-old DC101-treated kidney
compared to 2- and 3-week-old control kidney (*,**Po0.0001). Comparisons of the means were done by one-way analysis of variance , n¼ 5–9,
data on the y-axis is expressed in arbitrary units.
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suggesting a possible loss of proximal tubule characteristics as
cysts enlarge (*) or that other tubules also become cystic.
Some tubules had protein resorption droplets that stained
positive for PAS (red arrow). We found that ACE staining was
present in the proximal tubules of DC101-treated and control
kidney at 1 week of age (Figure 3e–h, white arrow points to
dilated tubule in DC101-treated kidney). At 2 weeks of age,
there was less ACE staining in the proximal tubules of control
kidney. Interestingly, 2-week-old DC101-treated kidney had
increased ACE staining in the cystic tubules (white arrow).
An increase in proximal tubule ACE has also been reported in
experimentally induced proteinuria and in other tubulo-
interstitial kidney diseases.10,11
Glomerular changes in mice treated with DC101 in the
perinatal period
At 1 week of age, many of the glomeruli from DC101-treated
mice were larger and more hypocellular then glomeruli from
control mice (Figure 4a, b). The glomerular changes in the
DC101-treated mice were consistent with previous reports in
which neonatal mice were exposed to VEGF blockade.2,3
Also, greater numbers of immature-appearing glomeruli in
the subcapsular renal cortex were noted in the DC101-treated
mice (yellow arrows). At 2 and 3 weeks of age, abnormal
glomeruli were still present in mice treated with DC101 in the
perinatal period (Figure 4c–f).
Urine protein and serum creatinine were measured from
2- and 3-week-old DC101-treated and control mice. The
urine from 3-week-old DC101-treated mice contained
significantly elevated protein levels compared to control mice
(Figure 5a). The serum creatinine from DC101-treated mice,
however, was not significantly different from control mice, at
either 2 or 3 weeks of age (Figure 5b). This was unexpected
since serum creatinine has been shown to be significantly
elevated in other perinatal models of VEGF signaling
blockade.3 Although 3-week-old DC101-treated kidney had
a paler appearance, it was not grossly larger then the control
kidney (Figure 5c).
Effect of combined DC101 and MF1 on postnatal kidney
development
The kidneys of mice treated with MF1 alone in the perinatal
period exhibited no histological changes and had normal
survival compared to control mice at 1, 2, and 3 weeks of age
(data not shown). In contrast, mice that were given a
combination of MF1 and DC101 in the perinatal period,
developed renal cysts and had increased mortality at 1 and 2
weeks of age compared to control mice (Figure 6). The
number and size of renal cysts, in DC101þMF1-treated
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Figure 2 | Localization of DC101 to glomeruli in 5-day-old kidney.
DC101 antibodies were injected into 5-day-old mice. Cryostat
sections were co-stained to detect DC101 localization (g, h, i, red
staining) and synaptopodin (d, e, f, green staining). At 2 h, DC101
antibody staining was found primarily in the glomeruli (white
arrows). Although control kidney had glomerular staining (f), no
significant DC101 antibody staining was detected (i). Nuclei were
stained blue with 40,6-diamidino-2-phenylindole dihydrochloride
(a– c – merged figures).
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Figure 3 | PAS and ACE staining in mice treated with DC101 in the
perinatal period. (a–d) A subgroup of cysts stained positive for PAS
in both 2- and 3-week-old kidney treated with perinatal DC101 (a, c),
black arrow. The largest cysts had little or no PAS staining (*). Some
tubules had protein resorption droplets (red arrow). Cysts were not
present in 2- and 3-week-old control kidney (b, d); however, PAS
staining was present in the brush borders of the proximal tubules.
(e–h) ACE staining was present in proximal tubules of DC101-treated
(e, f) and control kidney at 1 and 2 weeks of age (g, h). Note at 1
week, ACE staining is present in mildly dilated proximal tubule of
DC101-treated-kidney (white arrow). At 2 weeks, some dilated renal
cysts have increased ACE staining (white arrow).
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mice, were not significantly different from DC101-treated
mice at 2 weeks of age. Few mice treated with both DC101
and MF1 in the perinatal period survived beyond 3 weeks of
age. Therefore, although blockade of VEGFR-1 alone did not
adversely affect postnatal kidney growth, blockade of both
VEGFR-1 and VEGFR-2 caused the development of renal
cysts and increased mortality beyond that of mice treated
with VEGFR-2 antibodies alone.
Increased proliferation in cysts of 2- and 3-week old
DC101-treated mice
To determine if renal cyst formation was associated with
increased cell proliferation, Ki67 staining was performed in
DC101-treated mice. We found that DC101-treated mice had
increased Ki67 staining in epithelial cells lining the smaller
cysts at 1, 2, and 3 weeks of age (Figure 7a–g). At 3 weeks of
age, the large cysts of the DC101-treated kidneys had little or
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Figure 5 | Increased urine protein in 3-week-old mice treated with
DC101 in the perinatal period. (a) Three-week-old DC101-treated
mice had significantly more urine protein then 2-week-old DC101-
treated and 2-and 3-week-old control mice. (b) There was no
significant difference in serum creatinine between 2- and 3-week-old
DC101-treated and 2- and 3-week-old control mice. (c) Kidney from
3-week-old DC101-treated mice had a paler appearance then the
3-week-old control kidney.
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Figure 6 | Increased mortality in mice treated with both DC101
and MF1 in the perinatal period. (a–c) Mice treated with MF1
antibody in the perinatal period did not develop renal cysts (a). In
contrast, mice treated with both DC101þMF1(DþM) in the perinatal
period developed renal cysts at 2 and 3 weeks of age (b, c). (d) At 1
week of age, DþM-treated mice had significantly greater mortality
compared to control mice (*Po0.006). At 2 weeks of age, DþM mice
had significantly greater mortality compared to control mice and
DC101-treated mice (**Po0.0001). n¼ 15–40 animals/group for 1 and
2 weeks time points. Comparisons of the means were done by
one-way analysis of variance.
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Figure 4 | Abnormal glomeruli in mice treated with perinatal
DC101. (a, b) One-week-old DC101-treated kidney with enlarged,
hypocellular glomeruli (a), black arrow and small immature glomeruli
near capsule, yellow arrows. (c–f) Abnormal glomeruli in 2- and
3-week old DC101-treated kidney (c, e), black arrows. Red arrows
point to normal glomeruli in control kidney (b, d, f).
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Figure 7 | Increased proliferation in renal cysts of mice treated
with perinatal DC101. (a–f) Black arrows point to Ki67 staining in
DC101-treated mice at 1, 2, and 3 weeks of age (a, c, e). Control
kidney had less Ki67 staining of renal tubules (b, d, f). (g) DC101-
treated kidney at 1, 2, and 3 weeks of age had significantly more Ki67
staining then 1-, 2- and 3-week-old control kidney (*Po0.01,
**Po.004 and ***Po0.01, respectively) by Student’s t-test, n¼ 3–4.
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no Ki67 staining (*), but staining was still present in the
smaller cysts (black arrow). Caspase 3 staining was also
performed as a marker for apoptosis. There was no increase
in caspase 3 staining in the kidneys of DC101-treated mice at
any age tested, compared to control mice (data not shown).
VEGF protein levels in the kidneys of 2- and 3-week-old mice
treated with VEGFR-2-neutralizing antibodies
In order to determine if VEGF content was altered in the
kidneys of mice that developed renal cysts, following
perinatal DC101 administration, we measured VEGF protein
levels by Western blot analysis (Figure 8). We found that
VEGF protein levels from 1-, 2- and 3-week-old DC101-
treated kidneys were similar to that of age-matched control
kidneys. Therefore, alterations in VEGF protein were not
found to be present in the kidneys of DC101-treated mice
that develop renal cysts at 2 and 3 weeks of age.
DISCUSSION
Renal cystic disease is an important cause of renal
insufficiency and renal failure. Despite major advances in
understanding their genetic basis, the pathogenesis of cyst
formation is incompletely understood. Furthermore, there
has been little insight into the mechanism linking the
potentially lethal vascular malformations associated with the
epithelial-based kidney cysts. In the current study, we
demonstrated for the first time that brief but reversible
disruption of VEGF–VEGFR-2 signaling in the perinatal
period resulted in the development of renal cysts. We
transiently blocked VEGF/VEGFR-2 signaling using DC101,
an antibody to VEGFR-2 and found that kidneys of CD-1
mice developed renal cysts by 2 weeks of age. Our findings
demonstrate that VEGF/VEGFR-2 signaling is essential for
normal postnatal development of kidney tubules and that
disruption of this pathway may be a factor in the
development of postnatal renal cysts.
Our studies indicate that VEGFR-2 antibodies are
absorbed into the renal vasculature and then filtered through
the glomeruli. Owing to this pattern of absorption, DC101
may interfere with peritubular capillary growth and/or have a
direct effect on proximal tubule epithelium. Although the
mechanism of renal cyst development was not addressed in
these studies, our findings suggest that brief interruption of
VEGF/VEGFR-2 signaling during late nephrogenesis can
adversely affect proximal tubule growth in the postnatal
kidney. Studies using renal proximal tubule epithelial cell
lines suggest that VEGF/VEGFR-2 signaling may have both a
paracrine and autocrine effect on the kidney, first by
attracting endothelial cells to the proximal tubules and
second by enhancing growth of the proximal tubule epithelial
cells.12
In our model, DC101 was given to mice on days 2 and 4 of
life. Therefore, blockade of VEGFR-2 signaling should not
last beyond 1 week of life, based on the 3–4 day half-life of the
DC101 antibody. Since VEGF/VEGFR-2 signaling should be
intact at 2 and 3 weeks of age in the DC101-treated mice, we
predicted that VEGF/VEGFR-2 signaling would be increased
at 2 and 3 weeks of age and that this increase would be
associated with renal cysts formation. We were not, however,
able to demonstrate quantitative changes in VEGFR-2
phosphorylation between control and DC101-treated kidneys
by immunoprecipitation studies. Furthermore, VEGF protein
levels were similar between control and DC101-treated
kidneys at 1, 2, and 3 weeks of age. Therefore, we were
unable to demonstrate that a compensatory increase in
VEGF/VEGFR-2 signaling was associated with renal cyst
formation.
Interestingly, renal cysts only developed when DC101 was
given to mice in the first week of life. They did not develop
when DC101 was given at 2 weeks of age. This suggests that
there is a critical time point in postnatal development, that is,
perinatal period, in which VEGF/VEGFR-2 signaling is
essential for normal renal tubule formation. Mattot et al.13
demonstrated that VEGF164 and VEGF188 isoforms were
necessary for normal tubule development in the perinatal
period. In the absence of these isoforms, mice developed
dilated tubules at 6 days of life and early mortality. Therefore,
impairment in VEGF/VEGFR-2 signaling by either ligand or
receptor blockade may disrupt early postnatal renal tubule
development.
Abnormal glomerular function, renal ischemia, angioten-
sin II deficiency, and severe ureteric obstruction may also
cause renal tubule damage and dilation.14–16 Blockade of
VEGF has been shown to cause proteinuria secondary to
glomerular dysfunction.17,18 In 3-week-old mice we found
increased proteinuria consistent with glomerular dysfunction
in mice given DC101 in the perinatal period. When DC101
was given to mice that were 2 weeks old, they also developed
proteinuria but not renal cysts (data not shown). We cannot
exclude the possibility that proteinuria, during early post-
natal life, does contribute to renal cyst development;
however, a recent study in mice found that proteinuria was
associated with apoptosis.19 In our model, we found
increased proliferation in renal tubules and not apoptosis.
Furthermore, other murine models of proteinuria, such as
Heymann nephritis have not been associated with renal cyst
development making it unlikely that proteinuria, per se, leads
to renal cyst formation.
Autosomal-dominant PKD and acquired renal cystic
disease are conditions in which the development of renal
cysts can lead to impaired renal function or kidney failure.
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Kidney International (2006) 69, 1741–1748 1745
S McGrath-Morrow et al.: DC101 blockade leads to renal cyst formation o r i g i n a l a r t i c l e
Autosomal-dominant PKD patients have been shown to have
endothelial dysfunction and vascular abnormalities including
subarachnoid aneurysms.20,21 The mechanism, by which
polycystin mutations lead to vascular abnormalities, however,
has not been elucidated. Based on our results, it could be
speculated that the VEGF/VEGFR-2 signaling pathway is
involved downstream of the polycystin genes and that
disruption of the VEGF/VEGFR-2 pathway may account for
vascular and growth abnormalities in autosomal-dominant
PKD. In a recent study by Saadi-Kheddouci et al.,22
transgenic mice that overexpressed mutant b-catenin were
shown to develop renal cysts by 3 weeks of age. From these
findings the authors suggested that b-catenin may act
downstream of the polycystin genes. b-Catenin is important
for endothelial barrier function and regulates cell prolifera-
tion through Wnt signaling.23 VEGFR-2 has been shown to
interact with b-catenin by forming a complex with b-catenin
and VE cadherin.24,25 Therefore, it is possible that blockade
of VEGFR-2 by DC101 could disrupt endothelial cell barrier
function and kidney tubule proliferation by interfering with
the normal interaction between VEGF, VEGFR-2, and
b-catenin.
Mice treated in the perinatal period with both DC101 and
MF1 (an antibody to VEGFR-1) developed renal cysts and
had decreased survival compared to mice treated with DC101
antibody alone. The more severe phenotype in the
DC101þMF1-treated mice is consistent with VEGFR-1-
enhancing VEGF/VEGFR-2 signaling. Interestingly in our
model, mice treated with MF1 alone had no obvious
glomerular or tubule abnormalities. The role of VEGFR-1
in VEGF signaling is not completely understood. VEGFR-1
may relay growth or inhibitory signals depending on the
experimental system, animal age, and target endothelial cell
bed. Soluble VEGFR-1 has been shown to negatively regulate
VEGF and is elevated in the serum, amniotic fluid, and pla-
centa of women with pre-eclampsia.26 In contrast, mem-
brane-bound VEGFR-1 has been shown to induce VEGF/
VEGFR-2 phosphorylation through the placental growth
factor ligand.27,28
A potential drawback of this study is that VEGFR-2
antibody was only given to mice with a CD-1 background. It
is possible that CD-1 mice may have a genetic predisposition
to the development of renal cysts. Under normal circum-
stances, however, CD-1 mice are not prone to the develop-
ment of renal cysts. A recent study revealed that 2% of males
and 0.7% of female CD-1 mice died during the first 50 weeks
of life. Of mice that died of non-tumor causes, nephropathy
and glomerulonephritis were common causes of death;
however, no mice were noted to spontaneously develop renal
cysts.29
We also did not find cyst development in extra-renal
organs, such as the pancreas and liver. Several possibilities
may explain the absence of cysts in these organs. Extra-renal
organs may not develop cysts as easily as the kidney when
exposed to brief but reversible VEGFR-2 blockade. Also,
disruption of VEGF/VEGFR-2 signaling may need to take
place earlier in development for cysts to form in these other
organs. Alternatively, cyst development in the kidney may be
secondary to the direct effect of the antibody on the apical
surface of the proximal tubule epithelium. In our model, it is
unlikely that the apical surface of the liver or pancreas was
exposed to the DC101 antibody.
In summary, mice that received VEGFR-2 antibody in the
perinatal period developed renal cysts between 2 and 3 weeks
of age. Mice receiving both VEGFR-1 and -2 antibodies had a
greater mortality at 3 weeks of age compared to mice treated
with VEGFR-2 antibody alone. In contrast, VEGFR-1 anti-
body treated mice had a normal renal phenotype with
normal survival. These findings suggest that VEGF/VEGFR-2
signaling is critical for normal postnatal tubule development
in the kidney. Additional studies will focus on elucidating the
mechanisms by which impairment in VEGF/VEGFR-2
signaling leads to renal cyst development.
MATERIALS AND METHODS
All animal experiments were performed according to animal
protocols approved by the Animal Care Use Committee of the
Johns Hopkins University School of Medicine. CD-1 mice (Charles
River, Wilmington, MA, USA) were used for all experiments.
VEGF receptor antibodies
Neutralizing rat monoclonal anti-VEGFR-1 and anti-VEGFR-2
antibodies were provided by Imclone (New York, NY, USA). Mice
received either DC101, an antibody to VEGFR-2 (0.08 mg/dose), or
MF1, an antibody to VEGFR-1 (0.1 mg/dose) by intraperitoneal
injection. The specificity and neutralizing properties of these
antibodies have been validated in numerous prior studies.27,30,31
This dosing has been developed in prior studies aimed at growth
arrest of tumor blood vessels.32 Animals treated with DC101
received injections on days 2 and 4 of life. Animals treated with MF1
received injections on days 2, 4, and 6 days of life. All mice received
volumes of 50ml/dose. Control animals received an equivalent dose
of endotoxin-free rat immunoglobulin G serum on days 2, 4, and 6
of life or no treatment. To determine the combined effects of
VEGFR-1 and VEGFR-2 blockade on kidney development, one
group of mice received both DC101 and MF1 antibody on days 2
and 4 of life. Mice were killed and evaluated at weekly intervals up to
3 weeks of age.
Tissue processing and immunohistochemistry
From each animal, one kidney was placed in 10% formalin
overnight and then paraffin-embedded. Then, 3 and 5 mm
histological sections were cut and de-paraffinized using xylene.
For detection of the cell proliferation marker, Ki67 (Dako, cat. no.
M7249, Carpinteria, CA, USA, 1:300 dilution) antigen retrieval was
performed with citrate buffer for 20 min, followed by washing, and
blockade with 3% H2O2 for 15 min. Primary antibody was applied
for 30 min at room temperature then washed in phosphate-buffered
saline (PBS). For a negative control, rat immunoglobulin G was used
as the primary antibody. Secondary antibody was applied for 10 min
at room temperature, washed, processed as per the Vectastain
Universal Quick Kit (PK-8800) and developed with diaminobenzi-
dine (Dako No. K3468), counter-stained, dehydrated, and mounted
with permount. Active caspase 3 rabbit polyclonal antibody (ab
2302, Abcam, Cambridge, UK, 10 mg/ml) was used as above, for
1746 Kidney International (2006) 69, 1741–1748
o r i g i n a l a r t i c l e S McGrath-Morrow et al.: DC101 blockade leads to renal cyst formation
detection of apoptosis. For detection of angiotensin-converting
enzyme (Santa Cruz Biotechnologies, Santa Cruz, CA, USA, sc-12187,
1:500) primary antibody was applied for 1 h. Slides were then
washed in PBS and rabbit serum was applied as a block (1:25) for
30 min and washed. Secondary antibody (rabbit anti-goat Alexa
Fluor 594 Green, cat. no. A11080, Molecular Probes, Carlsbad, CA,
USA, 1:200) was applied for 30 min. Slides were washed, stained
with 40,6-diamidino-2-phenylindole dihydrochloride for 1 min,
washed again and mounted with hard set mounting media
(Vectashield, Birlingame, CA, USA, cat. no. H-1400). For PAS
staining, hydrated slides were oxidized in 0.5% periodic acid
solution for 5 min. Slides were rinsed in water, placed in Schiff
reagent (Sigma, St Louis, MO, USA) for 15 min and then washed for
5 min. Slides were counterstained with Mayer’s hematoxylin solution
for 1 min, dehydrated, and mounted with permount.
Antibody binding in kidney
Five-day-old mice were injected by intraperitoneal injection with
DC101 antibody (0.08 mg/kg). Adult mice were injected by
intraperitoneal injection with MF1 antibody (0.1 mg/kg). Control
mice were injected with equal volumes of saline. Mice were killed at
2 h post injection and kidneys were frozen in optimum cutting
temperature. Cryostat sections (10 mm) were cut and processed.
Sections were fixed in cold acetone for 10 min and washed with PBS.
In order to detect VEGFR-2 antibodies, rabbit anti-rat biotinylated
secondary antibody (Dako, cat. no. E0467) was added at a 1:50
dilution in PBS for 30 min, then washed with PBS. Texas Red
streptavidin (Molecular Probes) in a 1:200 dilution in PBS was then
added for 30 min. Synaptopodin (Research Diagnostic Inc., Con-
cord, MA, USA, cat. no. RDI-PRO65194) ready to use, a podocyte
marker to identify glomeruli, was added to the slides for 30 min,
then washed in PBS. Alexa Fluor 488 rabbit anti-mouse (Invitrogen,
Carlsbad, CA, USA, cat. no. A-11059) in a 1:200 dilution in PBS was
then added for 30 min and washed in PBS. 40,6-diamidino-2-
phenylindole dihydrochloride was then applied for 1 min. Slides
were washed in water and mounted with hard set mounting
media.
Western blot
Whole kidney homogenate was used for Western blot analysis.
Protein concentrations were determined using the Biorad DC
protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Lysates were loaded and run on a 12% SDS-polyacrylamide gel.
Each protein gel contained 60 mg of protein per lane. Gels were
transferred to nitrocellulose. Western blot analysis was performed
using a VEFG antibody (Santa Cruz sc-507, 1:2000 dilution), as
recommended in 5% blotto, PBS and 0.05% Tween for one hour at
room temperature. Blots were then washed three times in PBS-
Tween, incubated with a secondary antibody, goat anti-rabbit
(Amersham, cat. no. NA934PS, Arlington Heights, IL, USA, 1:3000
dilution) for 1 h then washed and developed using chemilumines-
cence (ECL) (RPN 2106; Amersham). For normalization of loading,
blots were stripped using western blot stripping buffer (Pierce Prod
No. 21059) as recommended and re-probed with actin mouse
monoclonal antibody (Santa Cruz sc-8432, 1:1000 dilution) and
processed as above.
Measurement of renal cyst size and number
The mean luminal diameter of the renal cyst (in arbitrary units) was
calculated using the Metamorph Offline version, 6.3 (Molecular
Devices Corporation, Downingtown, PA, USA). Renal cyst number
was counted from individual sections of kidney. Five random
sections from each slide (representing one kidney) were acquired
with an original magnification  20 lens. This was performed in a
blinded fashion.
Urine protein measurements
Urine was analyzed for total protein using a micro bicinchoninic
acid protein kit as per the manufacturer’s instructions (Pierce
Chemical Company, Rockford, IL, USA).
Serum creatinine levels
Blood samples were obtained after killing by cardiac puncture.
Serum creatinine levels were analyzed using a 557A Creatinine Kit
(Sigma Diagnostics, St Louis, MO, USA) and analyzed on a Cobas
Mira S Plus automated analyzer (Roche Diagnostics Corp.,
Indianapolis IN, USA).
Statistics
Statistical calculations were performed using the SPSS 12.0 statistical
package for Windows (Chicago, IL, USA) Differences in measured
variables between experimental and control groups were determined
using comparison of the means using a one-way analysis of variance
(Bonferroni and Tukey post hoc analysis of statistical differences, as
appropriate) and Student’s t-test (two-tailed, equal variance).
Statistical difference was accepted at Po0.05.
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